Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX) Receives $4.80 Av

Shares of Amneal Pharmaceuticals, Inc. (NASDAQ:AMRX – Get Free Report) have earned a consensus rating of “Moderate Buy” from the five brokerages that are covering the firm, MarketBeat Ratings reports. One analyst has rated the stock with a hold recommendation and four have assigned a buy recommendation to the company. The average 1-year target price […]

Related Keywords

Switzerland , Swiss , , Analyst Recommendations For Amneal Pharmaceuticals , Panagora Asset Management Inc , Amneal Pharmaceuticals , Metlife Investment Management , News Ratings For Amneal Pharmaceuticals Daily , Amneal Pharmaceuticals Price Performance , Hedge Funds Weigh In On Amneal Pharmaceuticals , Amneal Pharmaceuticals Inc , York Mellon Corp , Swiss National Bank , Amneal Pharmaceuticals Company Profile , Blackrock Inc , Nasdaq , Get Free Report , Marketbeat Ratings , National Bank , New York Mellon Corp , Life Investment Management , Asset Management , Get Free , Amneal Pharmaceuticals Daily , Nasdaq Amrx , Amrx , Medical , Ratings , Consensus ,